The potential role of Interferon (IFN) in the treatment of malignant disease is currently being evaluated. Some central nervous system (CNS) toxicity, usually manifested by drowsiness or confusion has been recorded with all IFN preparations, almost regardless of the dose and schedule (Priestman 1980 , Scott et al., 1981 and it was shown to be the major dose-limiting toxicity when high doses of IFN derived from Namalwa lymphoblastoid cells (HuIFN-aN) were administered by continuous i.v. infusion (Rohatiner et al., 1982 (Schaffler et al., 1982) . The clinical findings and the EEG changes were the same with both types of IFN and could not be attributed to biochemical changes though transient abnormalities of hepatic enzymes were observed. In 3 patients who had 2 cycles of IFN, similar EEG changes were observed on each occasion.
IFN was present in the CSF in only 1 patient. Low levels have previously been reported in patients receiving IFN systemically (Priestman 1980 , Salazar et al., 1982 . The mechanism accounting for these CNS effects is unclear though IFN has been shown to enhance neuronal excitability (Calvet & Gresser 1979) and enhanced levels of p67K Kinase, an IFN-induced enzyme, have been demonstrated in the brain of mice treated with IFN (Krust et al., 1982) . Mattson et al. (1982) noted very similar EEG changes in patients with oat-cell lung cancer receiving high doses of leucocyte HuIFN-azN. Whether these changes are dose dependent remains to be established.
